Lipid Metabolism Practice Questions

Q: Which of the following organs cannot utilize fatty acids for energy metabolism, except?

Brain. ### Explanation The correct answer is **Brain**. **Why the Brain cannot utilize Fatty Acids:** The brain is highly dependent on glucose as its primary fuel source. It cannot utilize long-chain fatty acids for energy for two main reasons: 1. **Blood-Brain Barrier (BBB):** Fatty acids are transported in the blood bound to albumin. This large albumin-fatty acid complex cannot cross the BBB. 2. **Enzymatic Deficiency:** Even if small amounts of fatty acids enter the brain, the rate of **beta-oxidation** is extremely slow. High rates of beta-oxidation would increase oxygen demand and generate reactive oxygen species (ROS), potentially causing oxidative damage to neurons. *Note: During prolonged starvation, the brain adapts to use **ketone bodies**, but it never utilizes fatty acids directly.* **Analysis of Incorrect Options:** * **Liver (A):** The liver is the central hub for lipid metabolism. It actively performs beta-oxidation of fatty acids to generate ATP, especially during fasting. * **Muscle (B):** Resting skeletal muscle and cardiac muscle prefer fatty acids as their primary energy source. They have a high density of mitochondria to support beta-oxidation. * **Kidney (D):** The renal cortex utilizes fatty acids as its main fuel source to provide the energy required for active tubular reabsorption. **High-Yield NEET-PG Pearls:** * **RBCs** also cannot utilize fatty acids because they lack **mitochondria** (the site of beta-oxidation). * The brain's inability to use fatty acids is a protective mechanism to prevent **hypoxia** and **oxidative stress**. * In the fasting state, the liver converts fatty acids into **ketone bodies** (acetoacetate and β-hydroxybutyrate), which are the only lipid-derived molecules that can cross the BBB to provide energy.

Q: Saturated acyl enzyme formation causes:

Freeing of PAN-SH site. This question pertains to the **Fatty Acid Synthase (FAS) complex**, a multi-enzyme system responsible for de novo lipogenesis. ### Explanation of the Correct Answer The FAS complex is a dimer where each monomer contains two essential thiol (-SH) groups: the **Phosphopantetheine (PAN-SH)** site and the **Cysteine (Cyst-SH)** site. The process of fatty acid synthesis occurs in a repeating cycle of four steps: condensation, reduction, dehydration, and reduction. 1. Initially, the growing acyl chain is attached to the **PAN-SH** site. 2. During the **condensation step** (catalyzed by 3-ketoacyl synthase), the acyl group is transferred from the Cyst-SH site to the PAN-SH site to react with a malonyl group. 3. Once the four-step cycle is complete, a **saturated acyl enzyme** is formed, which is still attached to the **PAN-SH** site. 4. To begin the next round of elongation (adding the next 2-carbon unit), the saturated acyl group must be **transferred from the PAN-SH site to the Cyst-SH site**. This translocation **frees the PAN-SH site**, allowing it to receive a new malonyl-CoA molecule. ### Why Incorrect Options are Wrong * **B. Freeing of Cyst-SH site:** This is incorrect because the saturated acyl group moves *to* the Cysteine site, thereby occupying it, not freeing it. * **D. None:** Incorrect, as the translocation mechanism is a fundamental step in the FAS cycle to allow for chain elongation. ### High-Yield Clinical Pearls for NEET-PG * **Rate-limiting enzyme:** Acetyl-CoA Carboxylase (requires Biotin). * **End product:** Palmitate (16-carbon saturated fatty acid). * **Reducing equivalent:** NADPH is the essential co-factor (primarily from the HMP Shunt). * **Location:** Occurs in the **cytosol** (the "Citrate-Malate Shuttle" transports Acetyl-CoA from mitochondria to cytosol). * **Functional Unit:** The FAS complex is active only as a **dimer** arranged in a "head-to-tail" configuration.

Q: Micelles are formed by:

Amphipathic lipids in water. **Explanation:** **1. Why the correct answer is right:** Micelles are spherical molecular aggregates formed by **amphipathic lipids** (molecules containing both a hydrophilic "head" and a hydrophobic "tail") when placed in an aqueous environment (water). When the concentration of these lipids reaches the **Critical Micellar Concentration (CMC)**, they spontaneously orient themselves so that the polar heads face the water while the non-polar tails are sequestered in the center, away from the solvent. This arrangement minimizes the free energy of the system. **2. Why the incorrect options are wrong:** * **Option A & C:** **Triacylglycerols (TAGs)** are purely non-polar (neutral) lipids. They lack a hydrophilic head and therefore cannot form micelles; instead, they form large, oily droplets that coalesce. In the gut, TAGs must be broken down into monoacylglycerols and fatty acids (which are amphipathic) before micelles can form. * **Option D:** **Cholesterol esters** are highly hydrophobic and non-polar. Unlike free cholesterol (which is weakly amphipathic), cholesterol esters are stored in the interior of lipoproteins or lipid droplets and do not form micelles. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Bile Salts:** These are the most biologically significant amphipathic lipids in the gut. They form **mixed micelles** with 2-monoacylglycerols and long-chain fatty acids to facilitate the absorption of fat-soluble vitamins (A, D, E, K) and dietary lipids. * **Liposomes vs. Micelles:** While micelles have a hydrophobic core, **liposomes** are formed by lipid bilayers (e.g., phospholipids) and have an aqueous center. * **Absorption Site:** Micelles deliver lipids to the brush border of **enterocytes** in the proximal ileum/jejunum for absorption. Failure of micelle formation leads to **steatorrhea**.

Q: Tangier's disease is characterized by which of the following?

Low or absence of HDL. **Explanation:** **Tangier’s Disease** is an autosomal recessive disorder caused by a mutation in the **ABCA1 gene** (ATP-Binding Cassette transporter A1). 1. **Why Option A is correct:** The ABCA1 transporter is essential for the efflux of cholesterol and phospholipids from peripheral cells to lipid-poor **ApoA-I**. This process is the rate-limiting step in the formation of nascent HDL. In Tangier’s disease, the absence of this transporter leads to a failure in HDL maturation and rapid degradation of ApoA-I in the kidneys. Consequently, patients exhibit **extremely low or near-zero levels of HDL** in the plasma. 2. **Why other options are incorrect:** * **Option B (Deficiency of LPL):** This characterizes **Type I Hyperlipoproteinemia** (Familial Chylomicronemia Syndrome), leading to massive hypertriglyceridemia. * **Option C (Low LDL):** While LDL levels may be slightly reduced in Tangier’s disease due to altered VLDL metabolism, the hallmark and diagnostic feature is the absence of HDL. Primary low LDL is seen in **Abetalipoproteinemia** (MTP gene mutation). * **Option D (Raised chylomicrons):** This is seen in LPL or ApoC-II deficiency, not ABCA1 mutations. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Sign:** Large, **orange-colored tonsils** (due to accumulation of cholesteryl esters in reticuloendothelial cells). * **Clinical Triad:** Low HDL, hepatosplenomegaly, and peripheral neuropathy. * **Biochemical Hallmark:** Severe Hypoalphalipoproteinemia. * **Risk:** Increased risk of premature coronary artery disease (CAD) due to defective reverse cholesterol transport.

Q: Leukotrienes are produced from which precursor molecule?

Arachidonic acid. **Explanation:** **Leukotrienes** are a family of inflammatory mediators belonging to a class of compounds called **Eicosanoids** (20-carbon fatty acid derivatives). 1. **Why Arachidonic Acid is Correct:** Arachidonic acid is a 20-carbon polyunsaturated fatty acid (PUFA) found in the phospholipids of cell membranes. Upon stimulation (e.g., inflammation), it is released by the enzyme **Phospholipase A2**. It then enters one of two major pathways: * **Lipoxygenase (LOX) pathway:** Specifically, 5-LOX converts arachidonic acid into Leukotrienes (LTA4, LTB4, LTC4, LTD4, and LTE4). * **Cyclooxygenase (COX) pathway:** Converts it into Prostaglandins and Thromboxanes. 2. **Why Other Options are Incorrect:** * **Cholesterol (A):** This is a steroid precursor used for synthesizing steroid hormones (cortisol, estrogen), bile acids, and Vitamin D, but not eicosanoids. * **Stearic acid (C):** A 18-carbon saturated fatty acid. While it can be desaturated and elongated, it is not the direct precursor for leukotrienes. * **Palmitic acid (D):** A 16-carbon saturated fatty acid; it is the first fatty acid produced during *de novo* fatty acid synthesis. **High-Yield Clinical Pearls for NEET-PG:** * **LTA4** is the precursor for all other leukotrienes. * **LTB4** is a potent **chemotactic agent** for neutrophils ("B" for "Bacteria/Binding" neutrophils). * **LTC4, LTD4, and LTE4** (Cysteinyl leukotrienes) are known as the **Slow-Reacting Substance of Anaphylaxis (SRS-A)**, causing potent bronchoconstriction and mucus secretion in asthma. * **Zileuton** inhibits 5-LOX, while **Montelukast/Zafirlukast** are leukotriene receptor antagonists (LTRAs) used in asthma management.

Q: In which type of hyperlipoproteinemia is the chylomicron level increased?

Type I. **Explanation:** **Type I Hyperlipoproteinemia (Familial Chylomicronemia Syndrome)** is characterized by a massive accumulation of **chylomicrons** in the plasma. This occurs due to a genetic deficiency of either **Lipoprotein Lipase (LPL)** or its essential cofactor, **Apolipoprotein C-II**. Since LPL is responsible for clearing triglycerides from chylomicrons and VLDL, its absence leads to severe hypertriglyceridemia. A classic diagnostic sign is "creamy" plasma that forms a supernatant layer upon standing. **Analysis of Incorrect Options:** * **Type IIb (Familial Combined Hyperlipidemia):** Characterized by elevations in both **LDL and VLDL**. Chylomicron levels are typically normal. * **Type III (Dysbetalipoproteinemia):** Caused by Apo-E deficiency, leading to the accumulation of **IDL and Chylomicron remnants** (Broad-beta disease), but not primary chylomicrons. * **Type IV (Familial Hypertriglyceridemia):** Characterized by isolated elevation of **VLDL**. Triglyceride levels are high, but chylomicrons are absent in the fasting state. **High-Yield Clinical Pearls for NEET-PG:** * **Fredrickson Classification:** Type I and Type V are the only types where fasting chylomicrons are present. * **Clinical Triad of Type I:** Eruptive xanthomas, Hepatosplenomegaly, and Recurrent Pancreatitis. * **Key Difference:** Unlike other types, Type I is **not** associated with an increased risk of coronary artery disease (CAD). * **Diagnosis:** The "Refrigeration Test" shows a creamy layer over clear infranatant in Type I.

Q: A child presents with hepatosplenomegaly and pancytopenia. Bone marrow shows "crumbled tissue paper appearance". It is due to accumulation of which substance?

Glucocerebroside. ### Explanation The clinical presentation of **hepatosplenomegaly**, **pancytopenia** (due to hypersplenism), and the pathognomonic **"crumbled tissue paper"** appearance of macrophages in the bone marrow is diagnostic of **Gaucher disease**, the most common lysosomal storage disorder. **1. Why Glucocerebroside is correct:** Gaucher disease is caused by a deficiency of the enzyme **β-Glucosidase** (also known as glucocerebrosidase). This deficiency leads to the accumulation of **glucocerebroside** within the lysosomes of macrophages. These overloaded macrophages are called "Gaucher cells," and their cytoplasm appears fibrillary or like "crumbled tissue paper" under the microscope. **2. Why the other options are incorrect:** * **Sphingomyelin:** Accumulates in **Niemann-Pick disease** (deficiency of sphingomyelinase). It presents with a "foam cell" appearance (vacuolated) and a cherry-red spot on the macula, but not the crumbled tissue paper look. * **Ganglioside (GM2):** Accumulates in **Tay-Sachs disease**. It is characterized by neurodegeneration and a cherry-red spot, but notably lacks hepatosplenomegaly. * **Galactocerebroside:** Accumulates in **Krabbe disease** (deficiency of galactocerebrosidase). It presents with "globoid cells" and severe demyelination, not hepatosplenomegaly. **Clinical Pearls for NEET-PG:** * **Enzyme Deficient:** Acid β-glucosidase / Glucocerebrosidase. * **Gaucher Cells:** PAS-positive macrophages with wrinkled paper cytoplasm. * **Skeletal Involvement:** Look for "Erlenmeyer flask deformity" of the distal femur and avascular necrosis of the femoral head. * **Biochemical Marker:** Elevated levels of **Chitotriosidase** are used for diagnosis and monitoring treatment. * **Treatment:** Enzyme Replacement Therapy (ERT) with Alglucerase or Imiglucerase.

Q: Where are glycolipids synthesized?

Endoplasmic reticulum. **Explanation:** The synthesis of glycolipids (specifically glycosphingolipids) is a multi-step process that primarily occurs within the membrane systems of the **Endoplasmic Reticulum (ER)** and the Golgi apparatus. 1. **Why the Endoplasmic Reticulum is correct:** The lipid backbone of most glycolipids, known as **ceramide**, is synthesized on the cytosolic face of the smooth ER. While the subsequent addition of sugar moieties (glycosylation) primarily occurs in the Golgi apparatus, the foundational assembly and the initial steps of sphingolipid synthesis are anchored in the ER. In the context of medical exams, the ER is recognized as the primary site for the synthesis of membrane lipids, including phospholipids and the ceramide base for glycolipids. 2. **Why other options are incorrect:** * **Mitochondria:** Primarily involved in ATP production, the Citric Acid Cycle, and beta-oxidation of fatty acids; they do not synthesize complex glycolipids. * **Cytosol:** While some initial precursors (like malonyl-CoA) are formed here, the complex assembly of hydrophobic glycolipids requires membrane-bound enzymes found in organelles. * **Peroxisomes:** These are responsible for the initial steps of **plasmalogen** synthesis and the oxidation of very-long-chain fatty acids (VLCFA), but not glycolipid assembly. **High-Yield Clinical Pearls for NEET-PG:** * **Ceramide** is the fundamental structural unit of all sphingolipids (Ceramide = Sphingosine + Fatty Acid). * **Sphingolipidoses:** Genetic deficiencies in the lysosomal enzymes that *degrade* glycolipids lead to storage diseases like **Gaucher’s** (glucocerebrosidase deficiency) and **Tay-Sachs** (hexosaminidase A deficiency). * **Site Summary:** Lipid synthesis = Smooth ER; Protein synthesis = Rough ER; Lipid/Protein modification = Golgi.

Q: A 10-year-old boy presents with a white ring around the cornea. Physical examination reveals corneal arcus and xanthoma on the Achilles tendon. His fasting blood cholesterol is >300 mg/dl, and triglycerides are within the normal limit. His father had a history of coronary heart disease. What is the most likely diagnosis?

Type II A Hyperlipoproteinemia. ### **Explanation** **Correct Answer: B. Type II A Hyperlipoproteinemia** The clinical presentation of **coronary heart disease (CHD)** at a young age, **corneal arcus**, and **tendon xanthomas** (specifically on the Achilles tendon) is classic for **Familial Hypercholesterolemia (Type IIa)**. * **Underlying Concept:** Type IIa is characterized by a deficiency or defect in **LDL receptors**, leading to decreased clearance of LDL from the plasma. This results in isolated elevation of **LDL cholesterol** (Total Cholesterol >300 mg/dl) while **Triglycerides (TG) remain normal**, as seen in this patient. --- ### **Why Incorrect Options are Wrong:** * **Type I (Familial Chylomicronemia):** Caused by Lipoprotein Lipase (LPL) or Apo C-II deficiency. It presents with extremely high **Triglycerides**, eruptive xanthomas, and pancreatitis, but *not* premature CHD or tendon xanthomas. * **Type II B (Combined Hyperlipidemia):** Characterized by elevations in both **LDL and VLDL**. Therefore, both cholesterol and **triglycerides** would be elevated, which contradicts the normal TG levels in this case. * **Type III (Dysbetalipoproteinemia):** Caused by Apo E deficiency, leading to the accumulation of IDL (remnants). It typically presents with **palmar xanthomas** and elevation of both cholesterol and triglycerides. --- ### **High-Yield Clinical Pearls for NEET-PG:** * **Tendon Xanthoma:** Pathognomonic for Type IIa Hyperlipoproteinemia. * **Palmar Xanthoma (Xanthoma Striatum Palmare):** Pathognomonic for Type III Hyperlipoproteinemia. * **Eruptive Xanthoma:** Associated with severe Hypertriglyceridemia (Type I, IV, V). * **Fredrickson Classification:** Remember that Type IIa is "Pure Hypercholesterolemia" (↑LDL), while Type IIb is "Mixed Hyperlipidemia" (↑LDL + ↑VLDL).

Q: Under metabolic conditions associated with a high rate of fatty acid oxidation, what does the liver produce?

Acetoacetate. **Explanation:** The correct answer is **Acetoacetate**. **Why it is correct:** Under conditions of high fatty acid oxidation (such as starvation, prolonged fasting, or uncontrolled diabetes mellitus), there is an overproduction of **Acetyl-CoA** via $\beta$-oxidation. This excess Acetyl-CoA exceeds the capacity of the TCA cycle (partly because oxaloacetate is being diverted for gluconeogenesis). The liver diverts this surplus Acetyl-CoA into the **Ketogenesis** pathway. Acetoacetate is the "primary" ketone body formed, which can then be reduced to $\beta$-hydroxybutyrate or spontaneously decarboxylated to acetone. **Why the other options are incorrect:** * **Glutamate:** This is an amino acid involved in transamination and nitrogen metabolism, not a direct product of fatty acid oxidation. * **Cholesterol:** While cholesterol is synthesized from Acetyl-CoA, its synthesis is inhibited during high fatty acid oxidation (low energy states/fasting) because the rate-limiting enzyme, HMG-CoA reductase, is inactivated. * **Glycine:** This is the simplest non-essential amino acid and is not a product of lipid catabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Ketogenesis:** Occurs exclusively in the **mitochondria of hepatocytes**. * **Rate-limiting enzyme:** **HMG-CoA Synthase** (Mitochondrial). Note that the cytosolic version of this enzyme is used for cholesterol synthesis. * **Utilization:** The liver **cannot** use ketone bodies for energy because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Ketone Bodies:** Acetoacetate and $\beta$-hydroxybutyrate are acidic; their accumulation leads to metabolic acidosis (Ketoacidosis).

Question 1

Which of the following organs cannot utilize fatty acids for energy metabolism, except?

Accepted Answer

Brain

Answer

Liver

Answer

Muscle

Answer

Kidney

Question 2

Saturated acyl enzyme formation causes:

Accepted Answer

Freeing of PAN-SH site

Answer

Freeing of Cyst-SH site

Answer

Both

Answer

None

Question 3

Micelles are formed by:

Accepted Answer

Amphipathic lipids in water

Answer

Triacylglycerol in a polar solvent

Answer

Triacylglycerol in the gut

Answer

Cholesterol esters

Question 4

Tangier's disease is characterized by which of the following?

Accepted Answer

Low or absence of HDL

Answer

Deficiency of LPL

Answer

Low LDL concentration

Answer

Raised chylomicrons

Question 5

Leukotrienes are produced from which precursor molecule?

Accepted Answer

Arachidonic acid

Answer

Cholesterol

Answer

Stearic acid

Answer

Palmitic acid

Question 6

In which type of hyperlipoproteinemia is the chylomicron level increased?

Accepted Answer

Type I

Answer

Type IIb

Answer

Type III

Answer

Type IV

Question 7

A child presents with hepatosplenomegaly and pancytopenia. Bone marrow shows "crumbled tissue paper appearance". It is due to accumulation of which substance?

Accepted Answer

Glucocerebroside

Answer

Sphingomyelin

Answer

Ganglioside

Answer

Galactocerebroside

Question 8

Where are glycolipids synthesized?

Accepted Answer

Endoplasmic reticulum

Answer

Mitochondria

Answer

Cytosol

Answer

Peroxisomes

Question 9

A 10-year-old boy presents with a white ring around the cornea. Physical examination reveals corneal arcus and xanthoma on the Achilles tendon. His fasting blood cholesterol is >300 mg/dl, and triglycerides are within the normal limit. His father had a history of coronary heart disease. What is the most likely diagnosis?

Accepted Answer

Type II A Hyperlipoproteinemia

Answer

Type I Hyperlipoproteinemia

Answer

Type II B Hyperlipoproteinemia

Answer

Type III Hyperlipoproteinemia

Question 10

Under metabolic conditions associated with a high rate of fatty acid oxidation, what does the liver produce?

Accepted Answer

Acetoacetate

Answer

Glutamate

Answer

Cholesterol

Answer

Glycine

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?